HMGB2 and esophageal squamous cell carcinoma: Furthermore, ROC curve analysis demonstrated that HMGB2 expression in CD3-CD56+ NK cells could effectively distinguish early-stage from advanced-stage ESCC patients, with an AUC of 0.82 (95% CI: 0.56–1.00, p < 0.01).